nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCB1—peripheral nervous system neoplasm	0.381	1	CbGaD
Canagliflozin—ABCC2—Vincristine—peripheral nervous system neoplasm	0.0542	0.124	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.0506	0.116	CbGbCtD
Canagliflozin—ABCC2—Etoposide—peripheral nervous system neoplasm	0.0497	0.114	CbGbCtD
Canagliflozin—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0414	0.0949	CbGbCtD
Canagliflozin—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0414	0.0949	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.0339	0.0777	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0287	0.0658	CbGbCtD
Canagliflozin—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0248	0.0569	CbGbCtD
Canagliflozin—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0231	0.0529	CbGbCtD
Canagliflozin—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0177	0.0405	CbGbCtD
Canagliflozin—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0165	0.0378	CbGbCtD
Canagliflozin—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0162	0.0371	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0111	0.0253	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0106	0.0243	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00971	0.0223	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00662	0.0152	CbGbCtD
Canagliflozin—Dapagliflozin—ABCB1—peripheral nervous system neoplasm	0.00237	1	CrCbGaD
Canagliflozin—SLC5A1—Hexose uptake—SLC2A1—peripheral nervous system neoplasm	0.00133	0.0463	CbGpPWpGaD
Canagliflozin—SLC5A2—Hexose uptake—SLC2A1—peripheral nervous system neoplasm	0.00133	0.0463	CbGpPWpGaD
Canagliflozin—SLC5A1—Orphan transporters—COX2—peripheral nervous system neoplasm	0.00131	0.0455	CbGpPWpGaD
Canagliflozin—SLC5A2—Orphan transporters—COX2—peripheral nervous system neoplasm	0.00131	0.0455	CbGpPWpGaD
Canagliflozin—ABCC2—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00119	0.0413	CbGpPWpGaD
Canagliflozin—UGT1A9—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00103	0.0359	CbGpPWpGaD
Canagliflozin—ABCC2—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00101	0.035	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—GNS—peripheral nervous system neoplasm	0.000684	0.0238	CbGpPWpGaD
Canagliflozin—SLC5A1—Carbohydrate metabolism—GNS—peripheral nervous system neoplasm	0.000684	0.0238	CbGpPWpGaD
Canagliflozin—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000649	0.0226	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000528	0.0184	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000528	0.0184	CbGpPWpGaD
Canagliflozin—SLC5A1—Carbohydrate metabolism—ENO2—peripheral nervous system neoplasm	0.000414	0.0144	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—ENO2—peripheral nervous system neoplasm	0.000414	0.0144	CbGpPWpGaD
Canagliflozin—Urethral disorder—Vincristine—peripheral nervous system neoplasm	0.000407	0.00268	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000405	0.0141	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000405	0.0141	CbGpPWpGaD
Canagliflozin—Nocturia—Epirubicin—peripheral nervous system neoplasm	0.000405	0.00267	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—peripheral nervous system neoplasm	0.000405	0.00267	CcSEcCtD
Canagliflozin—Infection—Topotecan—peripheral nervous system neoplasm	0.000404	0.00267	CcSEcCtD
Canagliflozin—Infection—Isotretinoin—peripheral nervous system neoplasm	0.000401	0.00265	CcSEcCtD
Canagliflozin—Infection—Tretinoin—peripheral nervous system neoplasm	0.000401	0.00265	CcSEcCtD
Canagliflozin—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000401	0.014	CbGpPWpGaD
Canagliflozin—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.000399	0.00263	CcSEcCtD
Canagliflozin—Shock—Isotretinoin—peripheral nervous system neoplasm	0.000397	0.00262	CcSEcCtD
Canagliflozin—Shock—Tretinoin—peripheral nervous system neoplasm	0.000397	0.00262	CcSEcCtD
Canagliflozin—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.000396	0.00261	CcSEcCtD
Canagliflozin—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.000396	0.00261	CcSEcCtD
Canagliflozin—Infection—Melphalan—peripheral nervous system neoplasm	0.000396	0.00261	CcSEcCtD
Canagliflozin—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.000395	0.00261	CcSEcCtD
Canagliflozin—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.000392	0.00259	CcSEcCtD
Canagliflozin—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.000392	0.00259	CcSEcCtD
Canagliflozin—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000391	0.0136	CbGpPWpGaD
Canagliflozin—Angiopathy—Alitretinoin—peripheral nervous system neoplasm	0.000391	0.00258	CcSEcCtD
Canagliflozin—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.000387	0.00255	CcSEcCtD
Canagliflozin—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.000377	0.00249	CcSEcCtD
Canagliflozin—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.000377	0.00249	CcSEcCtD
Canagliflozin—Angiopathy—Vincristine—peripheral nervous system neoplasm	0.000377	0.00248	CcSEcCtD
Canagliflozin—Erythema—Alitretinoin—peripheral nervous system neoplasm	0.000375	0.00247	CcSEcCtD
Canagliflozin—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.000375	0.00247	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.00247	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000373	0.013	CbGpPWpGaD
Canagliflozin—Hypotension—Melphalan—peripheral nervous system neoplasm	0.000373	0.00246	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—peripheral nervous system neoplasm	0.000369	0.00243	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—peripheral nervous system neoplasm	0.000367	0.00242	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cisplatin—peripheral nervous system neoplasm	0.000363	0.00239	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—peripheral nervous system neoplasm	0.000362	0.00239	CcSEcCtD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000361	0.0126	CbGpPWpGaD
Canagliflozin—Urethral disorder—Cisplatin—peripheral nervous system neoplasm	0.00036	0.00237	CcSEcCtD
Canagliflozin—ABCC2—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.000356	0.0124	CbGpPWpGaD
Canagliflozin—Vaginal infection—Epirubicin—peripheral nervous system neoplasm	0.000354	0.00234	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—peripheral nervous system neoplasm	0.000354	0.00234	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000352	0.00232	CcSEcCtD
Canagliflozin—Fatigue—Topotecan—peripheral nervous system neoplasm	0.000351	0.00232	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000349	0.0023	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000349	0.0023	CcSEcCtD
Canagliflozin—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.000348	0.0023	CcSEcCtD
Canagliflozin—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.000348	0.0023	CcSEcCtD
Canagliflozin—Constipation—Topotecan—peripheral nervous system neoplasm	0.000348	0.0023	CcSEcCtD
Canagliflozin—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000345	0.00228	CcSEcCtD
Canagliflozin—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000345	0.00228	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000344	0.00227	CcSEcCtD
Canagliflozin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000344	0.012	CbGpPWpGaD
Canagliflozin—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000344	0.00227	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000341	0.00225	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—peripheral nervous system neoplasm	0.000341	0.00225	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—peripheral nervous system neoplasm	0.000339	0.00224	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.00224	CcSEcCtD
Canagliflozin—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.000336	0.00222	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—peripheral nervous system neoplasm	0.000335	0.00221	CcSEcCtD
Canagliflozin—SLC5A2—Carbohydrate metabolism—SLC2A1—peripheral nervous system neoplasm	0.000334	0.0116	CbGpPWpGaD
Canagliflozin—SLC5A1—Carbohydrate metabolism—SLC2A1—peripheral nervous system neoplasm	0.000334	0.0116	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000333	0.0022	CcSEcCtD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000333	0.0116	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000333	0.0116	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000332	0.0115	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000332	0.0115	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000332	0.00219	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00033	0.00218	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00033	0.00218	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.00033	0.00217	CcSEcCtD
Canagliflozin—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.00033	0.00217	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000328	0.00216	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.00216	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.00216	CcSEcCtD
Canagliflozin—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.000325	0.00214	CcSEcCtD
Canagliflozin—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000323	0.00213	CcSEcCtD
Canagliflozin—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000322	0.00212	CcSEcCtD
Canagliflozin—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000321	0.00212	CcSEcCtD
Canagliflozin—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000321	0.00212	CcSEcCtD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00032	0.0111	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00032	0.0111	CbGpPWpGaD
Canagliflozin—Erythema—Cisplatin—peripheral nervous system neoplasm	0.00032	0.00211	CcSEcCtD
Canagliflozin—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.00032	0.00211	CcSEcCtD
Canagliflozin—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000319	0.00211	CcSEcCtD
Canagliflozin—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000319	0.00211	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000317	0.00209	CcSEcCtD
Canagliflozin—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000317	0.00209	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—peripheral nervous system neoplasm	0.000316	0.00208	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—peripheral nervous system neoplasm	0.000314	0.00207	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—peripheral nervous system neoplasm	0.000313	0.00207	CcSEcCtD
Canagliflozin—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000313	0.00207	CcSEcCtD
Canagliflozin—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000312	0.00206	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—peripheral nervous system neoplasm	0.00031	0.00205	CcSEcCtD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.000307	0.0107	CbGpPWpGaD
Canagliflozin—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.000305	0.00201	CcSEcCtD
Canagliflozin—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000304	0.00201	CcSEcCtD
Canagliflozin—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000301	0.00199	CcSEcCtD
Canagliflozin—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.0003	0.00198	CcSEcCtD
Canagliflozin—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.0003	0.00198	CcSEcCtD
Canagliflozin—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000298	0.00196	CcSEcCtD
Canagliflozin—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000298	0.00196	CcSEcCtD
Canagliflozin—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000297	0.00196	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—peripheral nervous system neoplasm	0.000295	0.00195	CcSEcCtD
Canagliflozin—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000294	0.00194	CcSEcCtD
Canagliflozin—Infection—Vincristine—peripheral nervous system neoplasm	0.000293	0.00193	CcSEcCtD
Canagliflozin—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000292	0.00193	CcSEcCtD
Canagliflozin—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000292	0.0101	CbGpPWpGaD
Canagliflozin—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.00191	CcSEcCtD
Canagliflozin—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00029	0.00191	CcSEcCtD
Canagliflozin—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00029	0.00191	CcSEcCtD
Canagliflozin—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000289	0.00191	CcSEcCtD
Canagliflozin—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000288	0.0019	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.00189	CcSEcCtD
Canagliflozin—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000286	0.00189	CcSEcCtD
Canagliflozin—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000286	0.00189	CcSEcCtD
Canagliflozin—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000286	0.00188	CcSEcCtD
Canagliflozin—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000286	0.00188	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000285	0.00188	CcSEcCtD
Canagliflozin—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000282	0.00186	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000279	0.00184	CcSEcCtD
Canagliflozin—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000277	0.00183	CcSEcCtD
Canagliflozin—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000276	0.00182	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.0018	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00027	0.00178	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00027	0.00178	CcSEcCtD
Canagliflozin—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000269	0.00178	CcSEcCtD
Canagliflozin—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000267	0.00176	CcSEcCtD
Canagliflozin—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000267	0.00176	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000264	0.00174	CcSEcCtD
Canagliflozin—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000264	0.00174	CcSEcCtD
Canagliflozin—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000262	0.00173	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000261	0.00172	CcSEcCtD
Canagliflozin—Infection—Cisplatin—peripheral nervous system neoplasm	0.000259	0.00171	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.0017	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000257	0.0017	CcSEcCtD
Canagliflozin—Rash—Topotecan—peripheral nervous system neoplasm	0.000257	0.00169	CcSEcCtD
Canagliflozin—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000256	0.00169	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000256	0.00892	CbGpPWpGaD
Canagliflozin—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000256	0.00169	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000255	0.00168	CcSEcCtD
Canagliflozin—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000255	0.00168	CcSEcCtD
Canagliflozin—Rash—Tretinoin—peripheral nervous system neoplasm	0.000255	0.00168	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000255	0.00168	CcSEcCtD
Canagliflozin—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000254	0.00168	CcSEcCtD
Canagliflozin—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000254	0.00168	CcSEcCtD
Canagliflozin—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000254	0.00168	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000254	0.00167	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000253	0.00167	CcSEcCtD
Canagliflozin—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000253	0.00167	CcSEcCtD
Canagliflozin—Constipation—Vincristine—peripheral nervous system neoplasm	0.000252	0.00166	CcSEcCtD
Canagliflozin—Rash—Melphalan—peripheral nervous system neoplasm	0.000251	0.00166	CcSEcCtD
Canagliflozin—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000251	0.00166	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00025	0.00165	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000249	0.00164	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000248	0.00163	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000246	0.00162	CcSEcCtD
Canagliflozin—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000244	0.00161	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000243	0.0016	CcSEcCtD
Canagliflozin—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000243	0.0016	CcSEcCtD
Canagliflozin—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000242	0.0016	CcSEcCtD
Canagliflozin—Nausea—Topotecan—peripheral nervous system neoplasm	0.000242	0.0016	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000241	0.00159	CcSEcCtD
Canagliflozin—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00024	0.00158	CcSEcCtD
Canagliflozin—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00024	0.00158	CcSEcCtD
Canagliflozin—Infection—Etoposide—peripheral nervous system neoplasm	0.000237	0.00157	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000237	0.00156	CcSEcCtD
Canagliflozin—Nausea—Melphalan—peripheral nervous system neoplasm	0.000237	0.00156	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.00156	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.00155	CcSEcCtD
Canagliflozin—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000233	0.00154	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000232	0.00153	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000231	0.00152	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.00023	0.00152	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.0015	CcSEcCtD
Canagliflozin—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000226	0.00149	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000225	0.00149	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000224	0.0078	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000224	0.0078	CbGpPWpGaD
Canagliflozin—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000223	0.00147	CcSEcCtD
Canagliflozin—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.00145	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000218	0.00144	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000217	0.00143	CcSEcCtD
Canagliflozin—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000217	0.00143	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000215	0.00142	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.00141	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000212	0.0014	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000208	0.00137	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000206	0.00136	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000206	0.00136	CcSEcCtD
Canagliflozin—Constipation—Etoposide—peripheral nervous system neoplasm	0.000204	0.00135	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000204	0.00135	CcSEcCtD
Canagliflozin—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000202	0.00134	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.00133	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.00131	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000196	0.00129	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000195	0.00129	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000195	0.00129	CcSEcCtD
Canagliflozin—SLC5A2—Disease—GNS—peripheral nervous system neoplasm	0.000194	0.00673	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—GNS—peripheral nervous system neoplasm	0.000194	0.00673	CbGpPWpGaD
Canagliflozin—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000193	0.00127	CcSEcCtD
Canagliflozin—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000193	0.00127	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000192	0.00127	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00019	0.00125	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000189	0.00125	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.00125	CcSEcCtD
Canagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000188	0.00654	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	0.000188	0.00653	CbGpPWpGaD
Canagliflozin—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000187	0.00123	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000186	0.00123	CcSEcCtD
Canagliflozin—Rash—Vincristine—peripheral nervous system neoplasm	0.000186	0.00123	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000186	0.00123	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000185	0.00122	CcSEcCtD
Canagliflozin—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000182	0.0012	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000176	0.00116	CcSEcCtD
Canagliflozin—Nausea—Vincristine—peripheral nervous system neoplasm	0.000175	0.00116	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000173	0.00602	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.00114	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000171	0.00113	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000171	0.00113	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.00113	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000169	0.00588	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000169	0.00588	CbGpPWpGaD
Canagliflozin—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000169	0.00112	CcSEcCtD
Canagliflozin—Rash—Cisplatin—peripheral nervous system neoplasm	0.000164	0.00108	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000164	0.00108	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000164	0.00108	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000164	0.00108	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—GNS—peripheral nervous system neoplasm	0.000162	0.00564	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GNS—peripheral nervous system neoplasm	0.000162	0.00564	CbGpPWpGaD
Canagliflozin—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.00104	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000158	0.00104	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—NME1—peripheral nervous system neoplasm	0.000156	0.00541	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NME1—peripheral nervous system neoplasm	0.000156	0.00541	CbGpPWpGaD
Canagliflozin—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000155	0.00102	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.001	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.001	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000151	0.00525	CbGpPWpGaD
Canagliflozin—Rash—Etoposide—peripheral nervous system neoplasm	0.000151	0.000994	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000151	0.000993	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—COX2—peripheral nervous system neoplasm	0.00015	0.0052	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—COX2—peripheral nervous system neoplasm	0.00015	0.0052	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000147	0.00512	CbGpPWpGaD
Canagliflozin—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000971	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000951	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000144	0.00501	CbGpPWpGaD
Canagliflozin—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000938	CcSEcCtD
Canagliflozin—Nausea—Etoposide—peripheral nervous system neoplasm	0.000142	0.000936	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000915	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000901	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000898	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000136	0.00473	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000136	0.00473	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PPP3R1—peripheral nervous system neoplasm	0.000135	0.00471	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PPP3R1—peripheral nervous system neoplasm	0.000135	0.00471	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000134	0.00464	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000134	0.00464	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.00088	CcSEcCtD
Canagliflozin—Infection—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000878	CcSEcCtD
Canagliflozin—Shock—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000869	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000868	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000866	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000131	0.00454	CbGpPWpGaD
Canagliflozin—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000858	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000847	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000834	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—GNS—peripheral nervous system neoplasm	0.000125	0.00435	CbGpPWpGaD
Canagliflozin—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000825	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000812	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000804	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000802	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000794	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—NME1—peripheral nervous system neoplasm	0.00012	0.00417	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—KNG1—peripheral nervous system neoplasm	0.000118	0.00409	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ENO2—peripheral nervous system neoplasm	0.000117	0.00408	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ENO2—peripheral nervous system neoplasm	0.000117	0.00408	CbGpPWpGaD
Canagliflozin—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000764	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000116	0.00402	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000763	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—COX2—peripheral nervous system neoplasm	0.000116	0.00402	CbGpPWpGaD
Canagliflozin—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000762	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000755	CcSEcCtD
Canagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000113	0.00394	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000113	0.00392	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—KNG1—peripheral nervous system neoplasm	0.000112	0.0039	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00011	0.00381	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000722	CcSEcCtD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000108	0.00376	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000706	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000705	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000702	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000699	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000698	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000668	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	9.87e-05	0.000651	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000649	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—ENO2—peripheral nervous system neoplasm	9.83e-05	0.00342	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ENO2—peripheral nervous system neoplasm	9.83e-05	0.00342	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—HGF—peripheral nervous system neoplasm	9.8e-05	0.00341	CbGpPWpGaD
Canagliflozin—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	9.8e-05	0.000646	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—peripheral nervous system neoplasm	9.61e-05	0.000634	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.49e-05	0.0033	CbGpPWpGaD
Canagliflozin—Pruritus—Epirubicin—peripheral nervous system neoplasm	9.48e-05	0.000625	CcSEcCtD
Canagliflozin—SLC5A2—Disease—SLC2A1—peripheral nervous system neoplasm	9.46e-05	0.00329	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SLC2A1—peripheral nervous system neoplasm	9.46e-05	0.00329	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—HGF—peripheral nervous system neoplasm	9.33e-05	0.00325	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	9.13e-05	0.000602	CcSEcCtD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	8.91e-05	0.0031	CbGpPWpGaD
Canagliflozin—Asthenia—Doxorubicin—peripheral nervous system neoplasm	8.89e-05	0.000586	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—peripheral nervous system neoplasm	8.86e-05	0.000584	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—peripheral nervous system neoplasm	8.77e-05	0.000578	CcSEcCtD
Canagliflozin—Rash—Epirubicin—peripheral nervous system neoplasm	8.44e-05	0.000557	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—peripheral nervous system neoplasm	8.44e-05	0.000556	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.3e-05	0.00289	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—BCHE—peripheral nervous system neoplasm	8.3e-05	0.00289	CbGpPWpGaD
Canagliflozin—Dizziness—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.000541	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—peripheral nervous system neoplasm	7.96e-05	0.000525	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.92e-05	0.00275	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.92e-05	0.00275	CbGpPWpGaD
Canagliflozin—Rash—Doxorubicin—peripheral nervous system neoplasm	7.81e-05	0.000515	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—TH—peripheral nervous system neoplasm	7.81e-05	0.00271	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TH—peripheral nervous system neoplasm	7.81e-05	0.00271	CbGpPWpGaD
Canagliflozin—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	7.81e-05	0.000515	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—ENO2—peripheral nervous system neoplasm	7.59e-05	0.00264	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	7.54e-05	0.00262	CbGpPWpGaD
Canagliflozin—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.36e-05	0.000486	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.41e-05	0.00223	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—BCHE—peripheral nervous system neoplasm	6.41e-05	0.00223	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.37e-05	0.00222	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GNAS—peripheral nervous system neoplasm	6.37e-05	0.00222	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ABCB1—peripheral nervous system neoplasm	6.25e-05	0.00217	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.25e-05	0.00217	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.12e-05	0.00213	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TH—peripheral nervous system neoplasm	6.03e-05	0.0021	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	5.37e-05	0.00187	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.33e-05	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTPN11—peripheral nervous system neoplasm	5.29e-05	0.00184	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTPN11—peripheral nervous system neoplasm	5.29e-05	0.00184	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	5.22e-05	0.00181	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	5.19e-05	0.00181	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	4.98e-05	0.00173	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.97e-05	0.00173	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GNAS—peripheral nervous system neoplasm	4.92e-05	0.00171	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.9e-05	0.0017	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.83e-05	0.00168	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.78e-05	0.00166	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.72e-05	0.00164	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	4.63e-05	0.00161	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.54e-05	0.00158	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.48e-05	0.00156	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	4.48e-05	0.00156	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	4.44e-05	0.00155	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.35e-05	0.00151	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	4.35e-05	0.00151	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	4.28e-05	0.00149	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.19e-05	0.00146	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—peripheral nervous system neoplasm	4.18e-05	0.00145	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—peripheral nervous system neoplasm	4.18e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	3.83e-05	0.00133	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.79e-05	0.00132	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.72e-05	0.00129	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.36e-05	0.00117	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRAS—peripheral nervous system neoplasm	3.18e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRAS—peripheral nervous system neoplasm	3.18e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—peripheral nervous system neoplasm	2.96e-05	0.00103	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—peripheral nervous system neoplasm	2.96e-05	0.00103	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.94e-05	0.00102	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	2.9e-05	0.00101	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.84e-05	0.000987	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	2.81e-05	0.000976	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.79e-05	0.00097	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	2.69e-05	0.000935	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.68e-05	0.000933	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.53e-05	0.00088	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.47e-05	0.000858	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNS—peripheral nervous system neoplasm	2.43e-05	0.000844	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	2.37e-05	0.000825	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	2.35e-05	0.000818	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NME1—peripheral nervous system neoplasm	2.33e-05	0.000809	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—peripheral nervous system neoplasm	2.33e-05	0.000809	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—peripheral nervous system neoplasm	2.33e-05	0.000809	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.26e-05	0.000787	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	2.24e-05	0.000779	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.24e-05	0.000779	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—COX2—peripheral nervous system neoplasm	2.24e-05	0.000779	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	2.23e-05	0.000776	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.22e-05	0.000771	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.13e-05	0.000739	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—peripheral nervous system neoplasm	2.05e-05	0.000714	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—peripheral nervous system neoplasm	2.05e-05	0.000714	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.04e-05	0.000709	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.04e-05	0.000708	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2e-05	0.000695	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.96e-05	0.000682	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	1.82e-05	0.000633	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.81e-05	0.00063	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.79e-05	0.000621	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.78e-05	0.00062	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.75e-05	0.000608	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000598	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000598	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.63e-05	0.000568	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	1.47e-05	0.000511	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.44e-05	0.000499	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000462	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.31e-05	0.000455	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.29e-05	0.000448	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.26e-05	0.000437	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	1.24e-05	0.000432	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.23e-05	0.000428	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.21e-05	0.000422	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.21e-05	0.00042	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.19e-05	0.000412	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TH—peripheral nervous system neoplasm	1.17e-05	0.000406	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.09e-05	0.000378	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.04e-05	0.000361	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.02e-05	0.000356	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	9.83e-06	0.000342	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	9.53e-06	0.000332	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	9.36e-06	0.000325	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	8.35e-06	0.00029	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	7.94e-06	0.000276	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	7.52e-06	0.000261	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	7.19e-06	0.00025	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	6.71e-06	0.000233	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.4e-06	0.000222	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	6.35e-06	0.000221	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.31e-06	0.000219	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.15e-06	0.000179	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.05e-06	0.000176	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	4.92e-06	0.000171	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	2.57e-06	8.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.25e-06	7.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.39e-06	4.83e-05	CbGpPWpGaD
